NCT06950814Recruiting
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Prognostic Impact of Adjuvant Therapy Following Surgical Resection in Primary Hepatic Sarcomatoid Carcinoma: A Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 30 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strategies. Given the rarity and high aggressiveness of primary hepatic sarcomatoid carcinoma, there is a lack of reliable clinical evidence on whether postoperative adjuvant therapy can benefit patients, resulting in the absence of established standard guidelines. Therefore, we conducted a single-center retrospective study to assess the potential benefits of postoperative adjuvant therapy for patients of primary hepatic sarcomatoid carcinoma.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 22 Apr 2025
- Start date
- 5 Apr 2025
- Primary completion date
- 3 May 2025
- Lead sponsor
- West China Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06950814
What you commit to
- Study type: Observational
- Planned participants: 50
- From 5 Apr 2025 to the primary completion date, 3 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
- patients with concurrent other malignancies during the course of PHSC;
Other
- patients diagnosed with other specific types of sarcomas;
- patients who were lost to follow-up or lacked essential clinical data.
Who the study is looking for
- patients who underwent liver resection
- patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital Coordinator of this site? Confirm its status | Chengdu | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.